Pipeline 044
044
PROGRESS – Approaching Lead Series
IL-12v ABD Fc
A next-generation potency-optimized IL-12 cytokine-antibody fusion molecule. Engineered to deliver an unprecedented therapeutic index for this drug class.
PIPELINE 044
After confidently addressing the safety and pharmacokinetic parameters of IL-12 with our 001 program, we sought to amplify the pharmacodynamic effect within the tumor microenvironment (TME).
oNKo-044 is a next-generation IL-12 cytokine-antibody fusion molecule with optimized potency, extended half-life, and powerful anti-tumor function.
By including a targeting arm to bias the activity of IL-12 to specific immune cell populations in the TME, we can retain full anti-tumour activity at a fraction of the dose previously required – all whilst retaining an excellent safety profile.
